Do you check AMH levels to decide on adjuvant chemotherapy in premenopausal patients with node-positive ER+ breast cancer?

The short answer is no. The decision to recommend adjuvant chemotherapy for premenopausal, node-positive, ER+ breast cancer is based on the tumor's biology, not the patient's AMH levels. Here are my thoughts:

Role of AMH: AMH levels are not used to decide on chemotherapy. They are used to counsel pa...